CLEC9A is a marker of cDC1s, but a specific cDC1 gene signature (Böttcher et al., 2018) did not associate with STAD patient survival irrespective of sGSN expression levels (Figures S5E and S5F), which suggests that the association of CLEC9A with patient survival in the low sGSN patient group might predominantly reflect DNGR-1 receptor function rather than intratumoral cDC1 abundance. The gene discussed is CLEC9A; the disease is gastric adenocarcinoma.